Pyrotinib Sensitizes 5-Fluorouracil-resistant HER2+ Breast 4 Cancer Cells to 5-Fluorouracil.

In conclusion,our findings suggest that pyrotinib could restore sensitivity of 5-FU-resistant HER2+breast cancer cells to 5-FU through downregulating the expression levels of TS andABCG2. PMID: 32727638 [PubMed - as supplied by publisher]
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Related Links:

Conditions:   Breast Cancer;   Brain Metastases;   HER2-positive Breast Cancer;   CNS Disease Interventions:   Drug: Tucatinib;   Drug: Pembrolizumab;   Drug: Trastuzumab Sponsors:   Reva Basho;   Merck Sharp & Dohme Corp.;   Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Frank-Kamenetskii A, Mook J, Reeves M, Boulanger CA, Meyer TJ, Ragle L, Jordan HC, Smith GH, Booth BW Abstract The influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. Here using in vivo and in vitro models we demonstrate the impact epithelial cells and the mammary microenvironment can exert on breast cancer cells. Under specific conditions, signals that originate in epithelial cells can induce phenotypic and genotypic changes in cancer cells. We ha...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Vera-Tizatl CE, Talamás-Rohana P, Vera-Hernández A, Leija-Salas L, Rodríguez-Cuevas SA, Chávez-Munguía B, Vera-Tizatl AL Abstract In order to establish cancer-type-specific electroporation protocols for breast cancer, electroporation was performed in vitro in two modalities: in-suspension and adhered cells. Electroporation of cell suspensions was carried out through commercial electroporation cuvettes whereas a novel electrode for electroporation of adhered cells was designed and manufactured aimed to preserve cell structure, to provide a closer model to an in vivo scenar...
Source: Electromagnetic Biology and Medicine - Category: Physics Tags: Electromagn Biol Med Source Type: research
CONCLUSION: The increasing use of chemotherapy as patients progressed to second and later lines and the substantial direct/indirect economic burden underscore an unmet need. The high number of 1L regimens highlights significant heterogeneity and a lack of consensus related to the management of HR+/HER2- MBC in routine practice. PMID: 32755262 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Publication date: Available online 10 August 2020Source: Pathology - Research and PracticeAuthor(s): Jing Zhao, Uma Krishnamurti, Chao Zhang, Jane Meisel, Zhimin Wei, Aili Suo, Ritu Aneja, Zaibo Li, Xiaoxian Li
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Condition:   Breast Cancer Metastatic Intervention:   Drug: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C Sponsor:   Dizal Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). Consistently, miR-155-5p results as differentially expressed in the breast cancer subgroups identified by the surrogate molecular classification in the CSS cohort and the PAM50 classifier in TCGA-BRCA dataset, with the TNBC and HER2-amplified tumors carrying the highest levels. Since the analysis of TCGA-BC dat...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Patients with both HER2+ and high expression level of TOP2A protein predicts poor prognosis in T1N0 breast cancer patients. Patients with double positive for TOP2A protein and HER2 may benefit from anthracycline-based regimens. PMID: 32780321 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Conditions:   Hormone Receptor Positive Breast Carcinoma;   HER2-negative Breast Cancer Intervention:   Drug: OP-1250 Sponsor:   Olema Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: The inter-observer correlation and the correlation with the automated scoring system of the Ki-67 index was good. 29.1% was the mean Ki-67 index in the ER/PR positive group and this value was within the acceptable range as per St Galen's recommendation.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Study